TMCnet News
DBV Technologies Announces Appointment of Michel de Rosen as Non-Executive Chairman of the Board of DirectorsMontrouge, France, March 5, 2019 DBV Technologies Announces Appointment of Michel de Rosen as Non-Executive Chairman of the Board of Directors Mr. de Rosen to succeed DBV’s co-founder, Dr. Pierre-Henri Benhamou, who will retire from the Board of Directors and join Scientific Advisory Board Chief Executive Officer, Daniel Tassé, has also been appointed to the Board of Directors DBV Technologies (Euronext: DBV – ISIN: FR0010417345 - Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced that the Board of Directors has appointed existing board member, Michel de Rosen, as Non-Executive Chairman of the Board. Mr. de Rosen succeeds DBV Technologies’ co-founder, Dr. Pierre-Henri Benhamou, who retired from his position as DBV’s Non-Executive Chairman and board member. Dr. Benhamou will join the Company’s Scientific Advisory Board, effective immediately. Additionally, Daniel Tassé, Chief Executive Officer of DBV Technologies, has been appointed to the Board, replacing Dr. Pierre-Henri Benhamou. With these changes, effective immediately, DBV’s Board consists of eight directors. “On behalf of DBV’s Board, I would like to thank Pierre-Henri for his leadership and ongoing commitment to this organization. We also welcome Daniel, as well as Michel and his expanded role, and look forward to our continued partnership in building a leading biopharmaceutical company,” said Dr. Torbjörn Bjerke, DBV Technologies Board Director. Mr. de Rosen has served on DBV’s Board of Directors since June 2018. He is currently Chairman of the Board of Faurecia, a global supplier of automotive equipment, and Chairman of the Board of Pharnext, a publicly-traded pharmaceutical company. Previously, he served as Chairman and Chief Executive Officer of Eutelsat, Chairman and Chief Executive Officer of ViroPharma and Chairman and Chief Executive Officer of Rhône-Poulenc Santé. Earlier in his career, Michel de Rosen held key positions at the French Ministries of Finance, Defense, Industry, and Telecommunications. “Michel brings extensive knowledge and strategic vision to the business. The Board is looking forward to working with Michel in his role as Chairman, leveraging his vast experience in corporate governance and in bringing new treatments to patients,” said Dr. Torbjörn Bjerke. “Over 15 years ago, Pierre-Henri had a remarkable vision of developing a novel immunotherapy, which aims to activate the immune system of patients through the skin using the Viaskin immunotherapy platform. We thank Pierre-Henri for his scientific discovery, his leadership in developing Viaskin Peanut as a potential treatment for peanut-allergic children and are very glad to have his continued counsel as a member of our Scientific Advisory Board, where we believe his input will be invaluable.” Michel de Rosen said, “It is my honor to succeed Pierre-Henri Benhamou, a remarkable innovator, a fine humanist, and a gentleman, as Chairman of the DBV Board. And it will be my privilege to work with Daniel Tassé, our very talented CEO, and our experienced leadership team to build a potentially leading biopharmaceutical company. I believe in the potential of the Viaskin technology. I believe it is unique and compelling and may have the potential to offer novel product candidates that could become transformational therapies for patients.” About DBV Technologies Forward Looking Statements DBV Investor Relations Contact DBV Media Contact Attachment |